CAS No. |
116094-23-6 |
|---|---|
中文名称 |
29-[2-[15-[(1H-咪唑-4-基)甲基]-6-[5-[(1H-咪唑-4-基)甲基]-17-氨基-11-(2-氨基-2-氧代乙基)-8-(3-氨基-3-氧代丙基)-2-异丁基-14-异丙基-4,7,10,13,16-五氧代-18-苯基-3,6,9,12,15-五氮杂十八烷酰胺基]-47-[[(3-氨基-1-羧基-3-氧代丙基)氨基甲酰基]]-88-[14-氨基-2-(3-氨基-3-氧代丙基)-11-(仲丁基)-5-(2-羧乙基)-8-异丙基-4,7,10,13-四氧代-3,6,9,12-四氮杂十四烷酰胺基]-53-(2-氨基-2-氧代乙基)-62-(3-氨基-3-氧代丙基)-77-(仲丁基)-24,56-双(2-羧乙基)-33,50,65-三(4-羟基苄基)-83-(1-羟乙基)-12,71,80-三(羟甲基)-18,30,36,59,68-五异丁基-21,39-二异丙基-27-甲基-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-二十六氧代-3,4,44,45,90,91-六硫杂-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-二十六氮杂双环[72.11.7]九十烷-42-羧酰胺基]乙酰胺基]-5-(4-氨基丁基)-17,20-二苄基-8-(羧甲基)-26-(3-胍基丙基)-14-(4-羟基苄基)-2,11-双(1-羟乙基)-4,7,10,13,16,19,22,25,28-九氧代-3,6,9,12,15,18,21,24,27-九氮杂三十二烷二酸 |
英文名称 |
29-(2-(15-((1H-imidazol-4-yl)methyl)-6-(5-((1H-imidazol-4-yl)methyl)-17-amino-11-(2-amino-2-oxoethyl)-8-(3-amino-3-oxopropyl)-2-isobutyl-14-isopropyl-4,7,10,13,16-pentaoxo-18-phenyl-3,6,9,12,15-pentaazaoctadecanamido)-47-((3-amino-1-carboxy-3-oxopropyl)carbamoyl)-88-(14-amino-2-(3-amino-3-oxopropyl)-11-(sec-butyl)-5-(2-carboxyethyl)-8-isopropyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-(sec-butyl)-24,56-bis(2-carboxyethyl)-33,50,65-tris(4-hydroxybenzyl)-83-(1-hydroxyethyl)-12,71,80-tris(hydroxymethyl)-18,30,36,59,68-pentaisobutyl-21,39-diisopropyl-27-methyl-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosaazabicyclo[72.11.7]dononacontane-42-carboxamido)acetamido)-5-(4-aminobutyl)-17,20-dibenzyl-8-(carboxymethyl)-26-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-2,11-bis(1-hydroxyethyl)-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazadotriacontanedioic acid |
别名 |
INSULIN ASPART;D04475;Insulin aspart (genetical recombination);Insulin aspart (genetical recombination) (jan);Insulin aspart (usan/inn);Insulin X 14;Novolog;Novolog (tn) |
标准英文名 |
29-(2-(15-((1H-imidazol-4-yl)methyl)-6-(5-((1H-imidazol-4-yl)methyl)-17-amino-11-(2-amino-2-oxoethyl)-8-(3-amino-3-oxopropyl)-2-isobutyl-14-isopropyl-4,7,10,13,16-pentaoxo-18-phenyl-3,6,9,12,15-pentaazaoctadecanamido)-47-((3-amino-1-carboxy-3-oxopropyl)carbamoyl)-88-(14-amino-2-(3-amino-3-oxopropyl)-11-(sec-butyl)-5-(2-carboxyethyl)-8-isopropyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-(sec-butyl)-24,56-bis(2-carboxyethyl)-33,50,65-tris(4-hydroxybenzyl)-83-(1-hydroxyethyl)-12,71,80-tris(hydroxymethyl)-18,30,36,59,68-pentaisobutyl-21,39-diisopropyl-27-methyl-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosaazabicyclo[72.11.7]dononacontane-42-carboxamido)acetamido)-5-(4-aminobutyl)-17,20-dibenzyl-8-(carboxymethyl)-26-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-2,11-bis(1-hydroxyethyl)-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazadotriacontanedioic acid |
分子式 |
C256H381N65O79S6 |
分子量 |
5825.64 |
精确分子量 |
5821.61 |
SMILES |
CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC=N3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC3=CNC=N3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C |
标准SMILES |
CC1NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CO)NC(=O)CNC(=O)C(CSSCC2NC(=O)C(CSSCC(NC(=O)C(NC(=O)C(CO)NC(=O)C(NC2=O)C(C)O)C(C)CC)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CC2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC1=O)C(C)C)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC1C=CC=CC=1)C(=O)NC(CC1C=CC=CC=1)C(=O)NC(CC1C=CC(O)=CC=1)C(=O)NC(C(C)O)C(=O)NC(CC(O)=O)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(NC(=O)CN)C(C)CC)C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC=N1)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC1C=CC=CC=1)C(C)C)C(C)C |
用途 |
Treatment of gestational diabetes mellitus; management of hyperglycemia in patients with type 1 and type 2 diabetes mellitus whose glycemic control is inadequate; used in combination with intermediate- or long-acting insulin for the control of fasting or preprandial hyperglycemia; suitable for use in insulin pump therapy. |
InChIKey |
WEDIKSVWBUKTRA-UHFFFAOYSA-N |
|
|
评论 |
|---|